February 25 - March 1, 2023
San Diego, CA, USA
February 25 - March 1, 2023
San Diego, CA, USA
Microfluidics has long offered the promise of smaller, more efficient and more biologically relevant assay systems. However, this has proven challenging due to the behavior of liquids at microliter volumes, bubbles and scale up for manufacturing. Microfluidic systems often also include other components such as environmental control units, optics and/or motion control devices.
Managing all of these elements using iterative design and prototyping can play a key role in successful project delivery. Use of low cost off the shelf mechanical products (e.g., peristaltic and syringe pumps, solenoid valves, programmable logic controllers) coupled with an ability to write basic code gives scientists and engineers the ability to rapidly prototype without the need for large cost overheads.
There is a large amount of, often free, support across variety on topics on many online platforms which make these technologies accessible to everyone. This approach comes with a steep early learning curve but can reduce initial equipment spend by over 10-fold and will allow for more efficient systems integration during product development.
Marrying these technologies with biochemical or cellular assays has the potential to bring disruptive change across fields as diverse as personalized medicine, diagnostics and drug screening.
Mark Lyons
HookeBio
Mark Lyons holds a Ph.D. in Biochemistry from the University of Oxford, a Masters in Immunology form the University of Birmingham and post-graduate certificates in Business Administration and the Internet of Things from Heriott-Watt University and Dublin City University. Mark is currently CEO of HookeBio, an SME developing a high-throughput microfluidic platform for MPS-based drug screening. He previously held positions as Team Leader at Radisens Diagnostics developing microfluidic assays and has led multidisciplinary teams in successful delivery of key milestones to multinational companies as well as successive European Space Agency projects. Lyons has also overseen product development from R&D to launch of FDA-regulated diagnostic tests during his time with Olympus Diagnostics. He has a background in assay and platform development and industrialization in the areas of microfluidics, cellular biology, immunoassay and clinical chemistry.